In June 2026, Hoshine Silicon (603260.SH) disclosed on the SSE e-interaction platform that its 0-degree body silicone and medical-grade liquid silicone rubber have completed pilot-scale validation and are about to enter the commercialization phase. This milestone marks a substantive step forward for domestic leading silicone enterprises in the high-end medical-grade product sector.

Two Product Lines Advancing in Parallel with Clear Application Scenarios

According to the company's disclosure, the two products that have completed pilot testing each have distinct focuses:

The 0-degree body silicone is primarily targeted at scenarios including realistic human models, medical gaskets, wearable devices, and high-end consumer electronics. Its core selling point lies in ultra-low hardness and high resilience, capable of simulating a soft tactile feel close to human skin. The medical-grade liquid silicone rubber is oriented toward medical catheters, medical device seals, wound dressings, and similar applications. These products feature ultra-low hardness, high resilience, and biocompatibility, meeting comfort requirements for prolonged human contact.

Additionally, both products show application potential in emerging fields such as flexible sensors and wearable health monitoring devices.

Medical-Grade LSR Market Growth Momentum Strong

From a downstream demand perspective, the growth logic for medical-grade silicone rubber is clear. According to industry research data, China's wrist-worn device shipments reached 73.9 million units in 2025, a year-on-year increase of 20.8%; the global silicone polymer market size is approximately $21.91 billion, with medical-grade silicone rubber being one of the faster-growing segments.

According to Fortune Business Insights, the medical-grade LSR market is projected to grow at a compound annual growth rate (CAGR) of 6.5% between 2026 and 2034, outpacing the overall LSR industry growth rate of 6.2%. As China's population aging accelerates, medical consumption upgrades, and wearable health devices become more widespread, the domestic market space for medical-grade silicone rubber is rapidly expanding.

Domestic Substitution Process Accelerating

Historically, the high-end medical-grade silicone rubber market has been dominated by international brands such as Dow, DuPont, and Elkem. Hoshine Silicon's product lines that have completed pilot testing not only fill the product gap for domestic manufacturers in ultra-low hardness body silicone and medical LSR but also benchmark against international standards in core indicators such as biocompatibility.

Hoshine Silicon also noted that the commercial progress of these products will depend on customer validation and market promotion, with some uncertainty regarding the specific timeline. However, it is foreseeable that with the completion of pilot validation and the initiation of commercialization, the domestic substitution process in China's medical-grade LSR market will significantly accelerate, providing downstream medical device and wearable device manufacturers with more cost-effective domestic material options.

More information, please click here.